Conference Coverage

VIDEO: Consider depression in patients with psoriasis


 

AT SDEF LAS VEGAS DERMATOLOGY SEMINAR

LAS VEGAS– When treating patients with psoriasis, “it is very important for us to treat the entire patient,” and consider the comorbidities, including depression, associated with psoriasis, Jeffrey M. Sobell, MD, said in a video interview at Skin Disease Education Foundation’s annual Las Vegas Dermatology Seminar.

Depression can be a particular concern for younger patients with more severe psoriasis, said Dr. Sobell of Tufts University, Boston.

When he sees patients aged 18-35 years with significant psoriasis in his practice, he has made it a habit to ask them about depression “and if they’ve ever had thoughts of hurting themselves,” and arranges for mental health follow-up visits for patients about whom he is concerned. “It’s something that’s hard to talk about, but so important,” he said.

Dr. Sobell disclosed relationships with multiple companies including AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Merck, Novartis, Regeneron, Sanofi, and Sun Pharma.

SDEF and this news organization are owned by the same parent company.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

Recommended Reading

Genital psoriasis is the worst: Patients sound off
MDedge Dermatology
Biologic approved for moderate to severe psoriasis in adolescents
MDedge Dermatology
Pediatric psoriasis carries sharply increased risk of selected autoimmune comorbidities
MDedge Dermatology
Psoriasis: Biologics bring potential for long-term remission off treatment
MDedge Dermatology
Biosimilars poised to save $54 billion over the next decade
MDedge Dermatology
Psoriasis patients face higher risk of alcohol-related death – but lower suicide risk
MDedge Dermatology
Guselkumab tops adalimumab for psychiatric comorbidities in psoriasis
MDedge Dermatology
Red Scaly Rash Following Tattoo Application
MDedge Dermatology
Moderate psoriasis: the new frontier for systemic therapies
MDedge Dermatology
Ustekinumab may reduce risk of nonmelanoma skin cancer
MDedge Dermatology